Welcome to our dedicated page for Goldenwell SEC filings (Ticker: GWLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Goldenwell's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Goldenwell's regulatory disclosures and financial reporting.
Goldenwell Biotech, Inc. notifies the SEC it will not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company states it could not, "without unreasonable effort or expense," compile all required financial statements and related disclosures and expects to file the report on or before April 15, 2026. The notice is signed by CEO Shuang Liu.
Goldenwell Biotech, Inc. reports third-quarter 2025 results that highlight its early-stage status and financial strain. For the quarter ended September 30, 2025, the company generated $25,000 in service revenue and no product sales, leading to a net loss of $7,985. For the first nine months of 2025, revenue from services was $62,500 and the net loss was $47,581, an improvement from a $103,962 loss a year earlier.
As of September 30, 2025, Goldenwell held $45,622 in cash, total assets of $220,410 and total liabilities of $315,233, resulting in negative stockholders’ equity of $94,823. The company has an accumulated deficit of $1,407,226 and a $95,588 related-party loan from its chief executive officer. Management and the auditors state that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and the business will require significant new financing to pursue its plan to scale nutraceutical and dietary supplement operations.
Goldenwell Biotech, Inc. reports minimal early-stage operations and continuing losses for the quarter and six months ended June 30, 2025. The company generated mainly service revenue of $37,500 in the six-month period, with only negligible product sales, and recorded a net loss of $39,596, bringing its accumulated deficit to $1,399,241 since inception.
At June 30, 2025, Goldenwell had total assets of $251,295, including cash of $76,507 and inventory of $174,788, against total liabilities of $350,633, resulting in negative stockholders’ equity. Management discloses a working capital deficit and an outstanding related-party loan of $95,588, and states that substantial doubt exists about the company’s ability to continue as a going concern.
The company plans to expand its nutraceutical and dietary supplements business but estimates it will need about $5,000,000 to build manufacturing facilities and scale operations. Management indicates that additional capital will likely need to come from debt or equity offerings, with no assurance such financing can be obtained.